← Back to Clinical Trials
Recruiting NCT05186623
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Trial Parameters
Condition Ulcerative Colitis
Sponsor Asan Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age 79 Years
Start Date 2022-02-05
Completion 2026-12-31
Interventions
Vedolizumab, Ustekinumab, or Tofacitinib
Brief Summary
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
Eligibility Criteria
Inclusion Criteria: * Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features * Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment Exclusion Criteria: * Not Korean ethnicity by family history * Inflammatory Bowel Disease Unclassified * Patients who already received colectomy due to ulcerative colitis
Related Trials
NCT07136116
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With M
View Trial →
NCT05186623
Prediction Model for Response to Biologics and Small Molecular Agent for UC
View Trial →
NCT06117423
Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease
View Trial →